Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Over 12,000 Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics, Inc. President and CEO Samuel Kintz executed the sale of 12,500 shares of common stock on June 17, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO, Director, and 10% Owner of Enliven Therapeutics, Inc. (ELVN), sold a total of 12,500 shares of common stock.
• The sales occurred on June 17, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kintz on November 15, 2024.
• One block of 10,502 shares was sold at a weighted average price of $22.0757 per share, with individual trades ranging from $21.5935 to $22.5793.
• A second block of 1,998 shares was sold at a weighted average price of $22.7494 per share, with individual trades ranging from $22.5945 to $22.9964.
• Following these transactions, Mr. Kintz beneficially owns 952,892 shares of Enliven Therapeutics common stock.
• The remaining shares are held indirectly by The Kintz & Egan Trust Dated March 30, 2019, for which Mr. Kintz serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale reduces ownership, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates negative implications, suggesting it's for personal financial planning rather than a reaction to new, adverse company information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled and not based on new, non-public information, mitigating concerns about opportunistic insider selling.

Negatives

• The sale by a key executive, director, and significant shareholder reduces insider ownership, which can sometimes be perceived negatively by investors as it does not signal increased confidence in the company's near-term prospects.

Risks

• While the sale was pre-planned, a reduction in insider ownership by a President and CEO could be interpreted by some investors as a lack of strong conviction, potentially leading to negative market sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

This Form 4 filing details an individual insider stock transaction and does not provide information for broader industry trend analysis or competitive positioning.

Stakeholder Impact

• Shareholders may observe a reduction in insider ownership, which could be a factor in their investment decisions, though the 10b5-1 plan context typically lessens concerns.

Next Steps

• The Reporting Person is obligated to provide detailed information on shares sold at each separate price upon request from the SEC, the Issuer, or a security holder.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, Insider Sale, Form 4, SEC Filing, Rule 10b5-1, Stock Transaction, CEO, Director, Beneficial Ownership